Semaglutide improves health-related quality of life versus placebo when added to standard of care in patients with type 2 diabetes at high cardiovascular risk (SUSTAIN 6)

Authors: Esteban Jódar, Marie Michelsen, William Polonsky, Rosangela Réa, Anna Sandberg, Tina Vilsbøll, Mark Warren, Signe Harring, Uwe Ziegler, Stephen Bain

Abstract

Aim: To assess what drives change in health-related quality of life (HRQoL) in type 2 diabetes in the SUSTAIN 6 trial and identify potential mediators of the treatment effect of semaglutide on HRQoL scores.

Materials and methods: The Short Form (SF)-36v2® questionnaire [comprising physical component summary (PCS) and mental component summary (MCS)] was used to assess changes in HRQoL from baseline to week 104, by treatment, in a prespecified analysis. This post-hoc analysis assessed change in PCS and MCS using the following factors as parameter/covariate, using descriptive statistics and linear regressions: major adverse cardiac events, hypoglycaemia, gastrointestinal adverse events, at least one episode of nausea, vomiting or diarrhoea, and change in glycated haemoglobin (HbA1c), body weight, blood pressure, heart rate and estimated glomerular filtration rate.

Results: Mean change in overall PCS score was +1.0 with semaglutide versus +0.4 with placebo, and +0.5 versus -0.2 for MCS. The treatment effect of semaglutide versus placebo (unadjusted estimate) was 0.7 [(95% confidence interval 0.1, 1.2); P = 0.018] on PCS and this was reduced when adjusted for change in HbA1c [0.4 (-0.2, 1.0), P = .167] and body weight [0.3 (-0.3, 0.9), P = .314]. The unadjusted treatment effect on MCS [0.7 (-0.0, 1.5), P = .054] was only reduced when adjusted for change in HbA1c [0.3 (-0.4, 1.1), P = .397]. When adjusting for all other parameters separately, the estimated effect of semaglutide on PCS and MCS qualitatively did not change.

Conclusions: Semaglutide improved HRQoL versus placebo; greater improvements with semaglutide versus placebo were possibly mediated, in part, by change in HbA1c and body weight. Clinicaltrials.gov: NCT01720446 (SUSTAIN 6).

Source: https://pubmed.ncbi.nlm.nih.gov/32227613/

Share the Post:

BDI Monthly Events

September 10Case Consultation
September 10: BDI hosts the San Diego-wide, monthly case consultation meeting (for mental health professionals working in the field of diabetes). Contact us at [email protected] if you are in the greater San Diego area and would like further information about this program.
September 14T1D Meet-up
September 14: Time for another T1D meet-up! GrownupT1Ds, a wonderful nonprofit here in southern California, which organizes fun social events for adults with type 1 diabetes here in southern California. This next one will be at 2 pm at Altar Society Brewing & Coffee Co, 230 Pine Ave, Long Beach. This event is free, but space is limited. Please RSVP at www.grownupt1ds.org
September 27Scripps Presentation
September 27: Dr. Polonsky (BDI President), will be presenting The Power of Psych at Scripps Whittier Diabetes Institute’s 2025 Updates in Diabetes Management, in La Jolla (CA). See: https://www.scripps.org/events/2025-updates-in-diabetes-management-september-27-2025